Allergan Inks $30M Deal With Restasis Buyers In Antitrust Suit
Allergan has struck a $30 million deal with buyers of dry-eye medication Restasis to end allegations that the pharmaceutical giant fought to keep a generic version of the medication off the...To view the full article, register now.
Already a subscriber? Click here to view full article